February 1, 2017
Astellas Pharma said on January 31 that it has obtained worldwide exclusive rights to develop and commercialize California-based Auration Biotech’s ruptured eardrum treatment AU-935. Astellas had struck an evaluation accord with Auration in October 2015, under which it held an...read more